Recent advances and future perspectives in the pharmacological treatment of < em > Candida auris < /em > infections

Expert Rev Clin Pharmacol. 2021 Jun 26. doi: 10.1080/17512433.2021.1949285. Online ahead of print.ABSTRACTINTRODUCTION: Candida auris is responsible for hospital outbreaks worldwide. Some C. auris isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby possibly leaving clinicians with few therapeutic options.AREAS COVERED: Antifungal agents both in early and in late phases of clinical development showing anti-C. auris activity.EXPERT OPINION: The research on antifungal agents active against C. auris has made important steps forward in recent years: (i) the development of drugs with novel mechanisms of action, such as ibrexafungerp and fosmanogepix, could provide a valid option against C. auris strains resistant to one or more older antifungals, including pan-resistant strains; (ii) rezafungin could allow once weekly administration of an active drug in the case of echinocandin-susceptible isolates, providing an effective outpatient treatment, while at the same time relieving selective pressure on novel classes; (iii) the development of oral formulations could allow step-down therapy and/or early discharge, or even to avoid hospitalization in mild or non-invasive diseases; (iv) according to available data, these novel agents show a good safety profile and a low potential for drug-drug interactions.PMID:34176393 | DOI:10.1080/17512433.2021.1949285
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research